Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
2007-6-26
pubmed:abstractText
Leukocyte infiltration is viewed as a pharmacological target in cerebral ischemia. We previously reported that reparixin, a CXCL8 receptor blocker that inhibits neutrophil infiltration, and related molecules can reduce infarct size in a rat model of transient middle cerebral artery occlusion (MCAO). The study aims were to compare the effects of reparixin in transient and permanent MCAO using varied treatment schedules and therapeutic windows to evaluate effects on long-term neurological deficits and late inflammatory response. Reparixin, administered for 1 to 3 days, 3.5 to 6 h after MCAO, ameliorates neurological function recovery and inhibits long-term inflammation. The infarct size reduction at 24 h, evaluated by TTC staining, is more pronounced in transient MCAO. MRI analysis identified a decrease in the progression of infarct size by reparixin that was more evident at 48 h in permanent MCAO, and was associated with a significantly improved recovery from long-term neurological deficits.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-10190685, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-10370250, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-10458589, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-10512924, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-10833314, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-10984541, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-11488537, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-11771949, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-11872910, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-12435860, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-12588778, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-12970087, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-1381529, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-14423467, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-14499943, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-14581618, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-14615545, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-15060322, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-15282370, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-15284446, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-15790949, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-15826819, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-1601103, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-16154293, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-16164828, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-16170078, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-16235560, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-16282546, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-16337691, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-16835629, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-2433817, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-2799870, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-3197789, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-3715945, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-7731977, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-7831706, http://linkedlifedata.com/resource/pubmed/commentcorrection/17592546-9409656
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1076-1551
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-33
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:articleTitle
The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats.
pubmed:affiliation
Mario Negri Institute, 20157 Milan, Italy.
pubmed:publicationType
Journal Article, Comparative Study